Dusseldorf - Delayed Quote EUR

Scholar Rock Holding Corp (2QK.DU)

7.70

+0.15

(+1.99%)

At close: September 27 at 7:30 PM GMT+2

Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now

We recently compiled a list of 10 Worst Falling Stocks To Buy Now. In this article, we will look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) ranks among the 10 worst falling stocks to buy now. To the new investor, the stock market can appear to be an unpredictable graph that has no inherent logic […]

Insider Monkey 2 days ago

SRRK
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., September 13, 2024--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 407,000 shares of its common stock to three newly hired employees, consisting of inducement stock options to

Business Wire 16 days ago

SRRK
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

CAMBRIDGE, Mass., September 10, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it has completed enrollment in the Phase 2 EMBRAZE trial designed to show proof-of-concept of apitegromab, an investigational selective myostatin inhibitor antibody, to safely preserve lean mu

Business Wire 19 days ago

SRRK
Scholar Rock Holding Corporation (SRRK): This Small-Cap Healthcare Stock Is A Good Buy Right Now

We recently compiled a list of the 10 Best Small-Cap Healthcare Stocks To Buy Now. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other small-cap healthcare stocks. Healthcare Sector: A Defensive Investment with Growth Potential in 2024 In difficult economic times, healthcare equities are […]

Insider Monkey 24 days ago

SRRK
Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

CAMBRIDGE, Mass., September 04, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the appointment of Beth Shafer, Ph.D., to the newly created role of Chief Business Officer. Ms. Shafer brings over 20 years of biopharmaceutical industry leadership and expertise to Scholar Ro

Business Wire 25 days ago

SRRK
Scholar Rock to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., August 29, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in September:

Business Wire last month

SRRK
Scholar Rock’s apitegromab shows promise for non-ambulatory SMA

Apitegromab is a monoclonal antibody believed to improve muscle strength by inhibiting myostatin activation.

Clinical Trials Arena last month

SRRK
Q2 2024 Scholar Rock Holding Corp Earnings Call

Q2 2024 Scholar Rock Holding Corp Earnings Call

Thomson Reuters StreetEvents last month

SRRK
Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass., August 08, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the second quarter ended June 30, 2024.

Business Wire last month

SRRK
Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

CAMBRIDGE, Mass., July 23, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its second quarter 2024 financial results and provide a business update on Thursday, August 8, 2024, at 8:15am ET.

Business Wire 2 months ago

SRRK
Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts?

We recently compiled a list of the 10 Most Shorted Stocks That Are Loved by Analysts. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other shorted stocks that are loved by analysts. Short selling is one of the more controversial ways of making […]

Insider Monkey 2 months ago

SRRK
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

CAMBRIDGE, Mass., June 24, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the first participants were dosed in the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, an investigational, highly selective myostatin inhib

Business Wire 3 months ago

SRRK
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting

CAMBRIDGE, Mass., June 03, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation, in combination with pembrolizumab in patients with advanced solid tumor

Business Wire 3 months ago

SRRK
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

CAMBRIDGE, Mass., May 28, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the America

Business Wire 4 months ago

SRRK
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

CAMBRIDGE, Mass., May 22, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the initiation of the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, a highly selective myostatin inhibitor, to preserve lean muscle mass in indiv

Business Wire 4 months ago

SRRK
Scholar Rock to Host Investor Day on May 22, 2024

CAMBRIDGE, Mass., May 14, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will host an Investor Day on Wednesday, May 22, 2024 beginning at 8:30 a.m. ET in New York City.

Business Wire 4 months ago

SRRK
Scholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed Analysis

Exploring the Financial Landscape and Strategic Progress Amidst Challenges

GuruFocus.com 4 months ago

SRRK
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress

CAMBRIDGE, Mass., May 07, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2024.

Business Wire 4 months ago

SRRK
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment. The active ingredients produce substantially greater weight loss than any other drugs on the market. I’d venture a guess that some investors assume that the best returns have already been had. However, there’s lots of evidence suggesting otherwise. Global obesity

InvestorPlace 5 months ago

GPCR

SRRK

LLY
Scholar Rock Holding Corp Reports Full Year 2023 Financial Results

Strategic Progress Amidst Increased Net Loss

GuruFocus.com 6 months ago

SRRK

Performance Overview

Return	2QK.DU	S&P 500
YTD	-57.69%	+20.30%
1-Year	+21.26%	+34.27%
3-Year	-31.86%	+40.97%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Scholar Rock Holding Corp (2QK.DU)

Scholar Rock Holding Corporation (NASDAQ:SRRK) Ranks High On The List Of Worst Falling Stocks To Buy Now

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in Obesity

Scholar Rock Holding Corporation (SRRK): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock’s apitegromab shows promise for non-ambulatory SMA

Q2 2024 Scholar Rock Holding Corp Earnings Call

Scholar Rock Reports Second Quarter 2024 Financial Results and Highlights Business Progress

Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts?

Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal

Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity

Scholar Rock to Host Investor Day on May 22, 2024

Scholar Rock Holding Corp (SRRK) Reports Q1 2024 Financial Results: A Detailed Analysis

Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress

3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

Scholar Rock Holding Corp Reports Full Year 2023 Financial Results

Performance Overview